Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes

European Journal of Medicinal Chemistry

Volumn 64, Issue , 2013, Pages 285-291

  Tailor, Navin K ^a   Boon, Hong L ^b   Sharma, Manu ^a  

^a JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

^b Drug Discovery Laboratory   (Malaysia)

Author keywords

COMPARE analysis; Cytotoxicity; Lantadenes; NCI

Indexed keywords

2 (3 NITROBENZYLIDENE) 22 BETA HYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; 2 (3 PHENYLPROP 2 EN 1 YLIDENE) 22 BETA HYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; 2 (4 CHLOROBENZYLIDENE) 22 BETA HYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; 2 (4 DIMETHYLAMINOBENZYLIDENE) 22 BETA HYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; 2 (4 FLUOROBENZYLIDENE) 22 BETA HYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; 2 (4 HYDROXY 3 METHOXYBENZYLIDENE) 22 BETA HYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; 2 (4 METHOXYBENZYLIDENE) 22 BETA HYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; 2 (4 METHYLBENZYLIDENE) 22 BETA HYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; 2 (PYRIDINE 4 YLMETHYLIDENE) 22 BETA HYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; 2 BENZYLIDENE 22 BETA HYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; 22BETA [(2 METHYL 1 OXO 2 BUTENYL)OXY] 3BETA HYDROXYOLEAN 12 EN 28 OIC ACID; 22BETA [(3 METHYL 1 OXO 2 BUTENYL)OXY] 3BETA HYDROXYOLEAN 12 EN 28 OIC ACID; 22BETA HYDROXYOLEAN 12 EN 28 OIC ACID; 3BETA,22BETA DIHYDROXY 3 OXOOLEAN 12 EN 28 OIC ACID; ANTINEOPLASTIC AGENT; CISPLATIN; LANTADENE A; LANTADENE B; TERPENOID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL REACTION; CLAISENE SCHMIDT REACTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; IN VITRO STUDY; LANTANA CAMARA; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; OLEANOLIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84877078781     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.04.009     Document Type: Article

References (19)

1. G.G. Rocha, M. Simões, K.A. Lúcio, R.R. Oliveira, M.A.C. Kaplan, and C.R. Gattass Natural triterpenoids from Cecropia lyratiloba are cytotoxic to both sensitive and multidrug resistant leukemia cell lines Bioorg. Med. Chem. 15 2007 7355 7360
2. A. Inada, T. Nakanishi, H. Tokuda, H. Nishino, A. Iwashina, and O.P. Sharma Inhibitory effects of Lantadenes and related triterpinoids on Epstein-Barr virus activation Planta Med. 61 1995 558 559
3. A. Inada, T. Nakanishi, H. Tokuda, H. Nishino, A. Iwashina, and O.P. Sharma Anti-tumor promoting activities of lantadenes on mouse skin tumors and mouse hepatic tumors Planta Med. 63 1997 272 274
4. J. Kaur, M. Sharma, P.D. Sharma, and M.P. Bansal Chemopreventive activity of lantadenes on two-stage carcinogenesis model in Swiss albino mice: AP-1 (c-jun), NF kB (p65) and p55 expression by ELISA and immunohistochemical localization Mol. Cell. Biochem. 314 2008 1 8
5. J. Kaur, M. Sharma, P.D. Sharma, and M.P. Bansal Antitumor activity of Lantadenes in DMBA/TPA induced skin tumors in mice: expression of transcription factors Am. J. Biomed. Sci. 2 2010 79 90
6. N.K. Tailor, V. Jaiswal, S.S. Lan, H.B. Lee, and M. Sharma Synthesis, selective cancer cytotoxicity and mechanistic studies of novel analogs of lantadenes Anticancer Agents Med. Chem. 2012 Dec 24 (Epub ahead of print)
7. M. Sharma, P.D. Sharma, M.P. Bansal, and J. Singh Lantadene A-induced apoptosis in human leukemia HL-60 cells Ind. J. Pharmacol. 39 2007 140 144
8. M. Sharma, P.D. Sharma, and M.P. Bansal Lantadenes and their esters as potential antitumor agents J. Nat. Prod. 71 2008 1222 1227
9. M. Sharma, P.D. Sharma, M.P. Bansal, and J. Singh Synthesis, cytotoxicity and antitumor activity of Lantadene A congeners Chem. Biodiver. 4 2007 932 939
10. M. Sharma, P.D. Sharma, and M.P. Bansal Synthesis and antitumor activity of novel pentacyclic triterpenoid Lantadene D Lett. Drug Des. Discov. 4 2007 201 206
11. M. Sharma, A. Rakhi, N. Dalal, and N. Sharma Design, synthesis and evaluation of Lantadene A congener with hydroxyl functionality in ring A as an antitumour agent Nat. Prod. Res. 25 2011 387 396
12. A.T. Nielsen, W.J. Houlihan, R. Adams, A.H. Blatt, V. Bockelheidie, T.L. Cairns, A.C. Cope, and D.J. Cram Organic Reactions 1968 John Wiley New York 1 438
13. M.R. Boyd, and K.D. Paull Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen Drug Develop. Res. 34 1995 91 104
14. S.L. Holbeck, J.M. Collins, and J.H. Doroshow Analysis of FDA-approved anti-cancer agents in the NCI 60 panel of human Tumor cell lines Mol. Cancer Ther. 9 2010 1451 1460
15. The 60-cell line test data of National Cancer Institute are accessible from the NSC numbers. http://dtp.nci.nih.gov/dtpstandard/dwindex/index.jsp.
16. D.W. Zaharevitz, S.L. Holbeck, C. Bowwerman, and P.A. Svetlik J. Mol. Graphics Modell. 20 2002 297
17. M. Sharma, and P.D. Sharma Optimization of lantadene isolation and preparation of 22β-hydroxy oleanonic acid Chem. Nat. Comp. 42 2006 442 444
18. O.P. Sharma, R.K. Dawra, H.P.S. Makkar, Isolation and partial purification of lantana.
19. R.H. Shoemaker The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 6 2006 813 823